Company Snapshot
- Ticker
- LLY
- Name
- LLY
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 921573719000.000000
- Volume
- 3,275,239
- Avg Volume (3M)
- 4,390,954
LLY
LLY
Last update recent
1027.51
+18.13
(+1.80%)
Market Cap
921573719000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 59419800000.000000
- EPS
- 20.50
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.56%
- Net Income
- 18412100000.000000
- Net Margin
- 30.99%
- Payout Ratio
- 28.28%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 50.05
- Forward P/E
- None
- P/S
- 15.51
- P/B
- 38.64
- Beta
- None
- Debt / Equity
- 1.78
- Current Ratio
- 1.55
- Return on Equity
- 0.77%
- Return on Assets
- 0.16%
Technicals & Returns
- Distance vs 200 DMA
- 26.52%
- 200 DMA
- 812.12
- Distance vs 50 DMA
- 10.04%
- 50 DMA
- 933.79
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metast Read more
- Name
- LLY
- Industry
- Drug Manufacturers - General
- CEO
- Mr. David A. Ricks
- Employees
- 43,000
- IPO Date
- 1972-06-01
- Phone
- 317 276 2000
- Address
- None
- Website
- https://www.lilly.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-08-15 • $1.3
Latest News
Curated headlines from premium sources.
2 Predictions for Eli Lilly in 2026
Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also looks ripe to announce a stock split.
Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says
Eli Lilly & Co. (NYSE: LLY)'s dominance in obesity therapeutics looks increasingly difficult to challenge, and Bank of America believes the market is still und…
Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)
Eli Lilly's recent long streak of correction for nine trading days calls for a look at the stock even as it has stabilised now. It's explained by stretched val…
Eli Lilly Just Delivered Fantastic News to Investors
Eli Lilly's weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market today and has a pipeline of promising…
Castleark Management LLC Reduces Stock Position in Eli Lilly and Company $LLY
Castleark Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE: LLY) by 42.1% in the undefined quarter, according to the company in i…
My Top 3 Healthcare Stocks to Buy in 2026
With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly rapidly and e…